» Articles » PMID: 22155502

Natural Killer Cell Differentiation from Hematopoietic Stem Cells: a Comparative Analysis of Heparin- and Stromal Cell-supported Methods

Overview
Date 2011 Dec 14
PMID 22155502
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells differentiated from hematopoietic stem cells (HSCs) may have significant clinical benefits over NK cells from adult donors, including the ability to choose alloreactive donors and potentially more robust in vivo expansion. Stromal-based methods have been used to study the differentiation of NK cells from HSCs. Stroma and cytokines support NK cell differentiation, but may face considerable regulatory hurdles. A recently reported clinical-grade, heparin-based method could serve as an alternative. How the stromal-based and heparin-based approaches compare in terms of NK cell generating efficiency or function is unknown. We show that compared with heparin-based cultures, stroma significantly increases the yield of HSC-derived NK cells by differentiating less-committed progenitors into the NK lineage. NK cells generated by both approaches were similar for most NK-activating and -inhibiting receptors. Although both approaches resulted in a phenotype consistent with CD56(bright) stage IV NK cells, heparin-based cultures favored the development of CD56(+)CD16(+) cells, whereas stroma produced more NK cell immunoglobulin-like receptor-expressing NK cells, both of which are markers of terminal maturation. At day 21, stromal-based cultures demonstrated significantly more IL-22 production, and both methods yielded similar amounts of IFN-γ production and cytotoxicity by day 35. These findings suggest that heparin-based cultures are an effective replacement for stroma and may facilitate clinical trials testing HSC-derived NK cells.

Citing Articles

Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies-Comparative Characterization of Current Protocols.

Budagova T, Efremova A, Usman N, Mokrousova D, Goldshtein D Int J Mol Sci. 2025; 26(3).

PMID: 39940874 PMC: 11816922. DOI: 10.3390/ijms26031107.


Suppression of CD56 NK cells in breast cancer patients is associated with the PD-1 and TGF-βRII expression.

Arianfar E, Khandoozi S, Mohammadi S, Memarian A Clin Transl Oncol. 2022; 25(3):841-851.

PMID: 36414921 DOI: 10.1007/s12094-022-02997-3.


Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?.

Damele L, Spaggiari G, Parodi M, Mingari M, Vitale M, Vitale C Cancers (Basel). 2022; 14(18).

PMID: 36139598 PMC: 9496735. DOI: 10.3390/cancers14184439.


Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C NK cells to target myeloid leukemia.

Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K Mol Ther. 2021; 29(12):3410-3421.

PMID: 34174441 PMC: 8636174. DOI: 10.1016/j.ymthe.2021.06.018.


Overcoming the UCB HSCs -Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways.

Shokouhifar A, Sarab G, Yazdanifar M, Fereidouni M, Nouri M, Ebrahimi M Cancer Cell Int. 2021; 21(1):298.

PMID: 34098947 PMC: 8185927. DOI: 10.1186/s12935-021-01983-z.


References
1.
Kim D, Kim J, Sohn S, Sung W, Suh J, Lee K . Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol. 2004; 125(2):217-24. DOI: 10.1111/j.1365-2141.2004.04891.x. View

2.
Cooley S, Trachtenberg E, Bergemann T, Saeteurn K, Klein J, Le C . Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2008; 113(3):726-32. PMC: 2628378. DOI: 10.1182/blood-2008-07-171926. View

3.
Siewe B, Kalis S, Le P, Witte P, Choi S, Conway S . In vitro requirement for periostin in B lymphopoiesis. Blood. 2011; 117(14):3770-9. PMC: 3083296. DOI: 10.1182/blood-2010-08-301119. View

4.
Najjam S, Mulloy B, Theze J, Gordon M, Gibbs R, Rider C . Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites. Glycobiology. 1998; 8(5):509-16. DOI: 10.1093/glycob/8.5.509. View

5.
Rubnitz J, Inaba H, Ribeiro R, Pounds S, Rooney B, Bell T . NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010; 28(6):955-9. PMC: 2834435. DOI: 10.1200/JCO.2009.24.4590. View